Related Experiment Video

Updated: May 11, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles

Qiu Zhang1, Fei Li

  • 1Department of Analytical Chemistry, School of Chemistry and Chemical Engineering, Shandong University, 27, South Shanda Road, 250100, Jinan, Shandong, China. zhangqiufcn@yahoo.com.cn.

Current Pharmaceutical Design
|April 30, 2013
PubMed

Insights

Therapeutic nanoparticles offer a promising strategy to overcome multidrug resistance (MDR) in cancer by combating the P-glycoprotein (P-gp) efflux pump. These nanoparticles enhance treatment efficacy and reduce toxicity in chemotherapy.

Area of Science:

  • Oncology
  • Nanomedicine
  • Pharmacology

Background:

  • Multidrug resistance (MDR) significantly hinders effective cancer chemotherapy.
  • P-glycoprotein (P-gp) mediated drug efflux is a primary mechanism of MDR in cancer cells.
  • Overexpression of P-gp leads to the removal of chemotherapeutic agents, reducing treatment success.

Purpose of the Study:

  • To review recent advancements in using therapeutic nanoparticles (NPs) to overcome P-gp-mediated MDR.
  • To discuss the strategies and advantages of employing NPs in cancer therapy against MDR.
  • To highlight how NPs can circumvent P-gp efflux mechanisms.

Main Methods:

  • Review of recent scientific literature on therapeutic nanoparticles and cancer MDR.
  • Analysis of studies focusing on P-gp efflux pump inhibition by NPs.
  • Examination of NP-based strategies to enhance drug delivery and efficacy in resistant cancers.

Main Results:

  • Therapeutic NPs demonstrate enhanced efficacy in overcoming P-gp-mediated MDR.
  • NPs offer reduced toxicity compared to conventional small molecule chemotherapeutics.
  • Various NP strategies effectively circumvent the P-gp efflux mechanism.

Conclusions:

  • Therapeutic nanoparticles represent a viable approach to combat P-gp-mediated MDR in cancer.
  • NPs provide a promising platform for improving cancer treatment outcomes.
  • Further research into NP-based therapies can revolutionize cancer care.

More Related Videos

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...